Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII ... ( LACHEN Switzerland and HO...)

Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies

Date:8/26/2009

LACHEN, Switzerland and HOBOKEN, N.J., Aug. 26 /PRNewswire/ -- Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide. Globally, 75% of the hemophilia cases go undiagnosed or untreated.

Octapharma AG, the third largest plasma products manufacturer in the world, recently brought together many of the most respected blood coagulation disorder researchers for two symposia on this important issue during the International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress in Boston. Octapharma was one of only five Platinum Sponsors at the ISTH Congress, which attracted approximately 7,500 representatives of the medical and research community as well as many patients.

Clinical experts noted during the symposia that up to 40 percent of previously untreated patients (PUPs) with hemophilia A develop the most serious clinical complication of FVIII replacement therapy - inhibitory antibodies - which can result in uncontrolled hemorrhage, increased hospitalizations and joint damage, resulting in increased morbidity and mortality.

"We brought the international community together to confront this issue because our worldwide commitment to hemophilia A patients dates back to Octapharma's formation 25 years ago," said Octapharma AG Vice Chairman '/>"/>

SOURCE Octapharma AG
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
2. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma

Post Your Comments:

(Date:6/18/2013)... -- Actavis, Inc. (NYSE: ACT ) today announced that ... and Exchange Commission (SEC) a registration statement on Form S-4 ... plc (NASDAQ: WCRX ), which included a ... (the "Form S-4"). As previously announced on May ... into a definitive agreement pursuant to which Actavis will acquire ...

(Date:6/18/2013)... , June 18, 2013 Royal Philips ... was named Overall Performance Leader in Imaging Equipment in ... Infrastructure report. Philips also received Best in KLAS and ... products: Ingenuity Core 128 Computed Tomography (CT), Ingenia ... PageWriter TC70 cardiograph. The annual Best in KLAS Awards: ...

(Date:6/18/2013)... , June 18, 2013 Millennium HealthCare ... has entered into an exclusive 25-year Supply and ... with eWellness Corporation ("EWC") for its Distance Monitored ... to use physical therapy program is a critical ... cardiovascular disease," said Chris Amandola , president, ...

Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2 Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3 Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4 Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5 Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6 Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7 Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2 Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3

[0] Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition [0] Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS [0] Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions

... Therapeutics, Inc. today,announced completion of a Phase ... kappa opioid agonist, CR845, under development for ... drug candidate was safe and,well-tolerated after intravenous ... expected to be associated with clinical analgesic ...

... CyberKnife System at Oklahoma ... CyberKnife Center, ... global leader in the field of radiosurgery,announced today that the first ... was recently,installed at the Oklahoma CyberKnife, LLC in Tulsa, OK. The ...

Cached Medicine Technology:Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 2 New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2 New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3 New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4

Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times

(Date:6/19/2013)... release is available in Spanish . ... of neglected diseases, it goes by the name of the ... was devoted to conditions that accounted for 90 per cent ... imbalance that the Drugs for Neglected Diseases initiative (DNDi) came ... the organization has been granted the BBVA Foundation Frontiers of ...

(Date:6/19/2013)... View Terrace, California (PRWEB) June 19, 2013 ... announce the launch of new websites. These online links are ... like Organic Septic Tank cleaner, Organic Odor Control Mold Magician ... completely safe for fish and animals in the water as ... harmful waste and sludge buildup that can accumulate at the ...

(Date:6/19/2013)... Researchers at Moffitt Cancer Center and colleagues at Louisiana ... prostate cancers that require immediate therapy. It relies on ... The goal is to better predict a prostate cancer,s ... study was published in the online journal PLOS ... prostate cancer accounts for 20 percent of all cancers ...

(Date:6/19/2013)... AZ (PRWEB) June 19, 2013 Guests at ... healthy, wealthy and wise even if they don’t go to ... does require some early thought. , Crafty ... when they take advantage of the pet-friendly Scottsdale Paradise Valley ... Package . With at least 14 days advance notice, guests ...

(Date:6/19/2013)... 19, 2013 In 2011, the value ... 710 million. Generic drugs form the largest sector, accounting ... The pharmaceutical industry is a significant contributor to the ... country’s GDP. Approximately 50% of the total domestic chemical ... industry. Hemofarm, Galenika and Zdravlje Actavis are key participants ...

Breaking Medicine News(10 mins):Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2 Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3 Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4 Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5 Health News:Effective Environmental Services Launch New Websites to Serve Customers 2 Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2 Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2 Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3 Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4 Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2

[0] DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation [0] Effective Environmental Services Launch New Websites to Serve Customers [0] Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers [0] Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley [0] Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com

... The Campaign for Tobacco-Free Kids applauds U.S. Senators Barbara ... legislation that gives the U.S. Food and Drug Administration (FDA) ... down on tobacco marketing and sales to kids. The ... The House has approved similar legislation, and Congress is expected ...

... , WASHINGTON, June 11 The Campaign for ... for voting today to approve historic legislation that gives the ... products, including the authority to crack down on tobacco marketing ... bipartisan bill 79 to 17. The House has approved ...

... The Campaign for Tobacco-Free Kids applauds U.S. Senators Blanche Lincoln ... that gives the U.S. Food and Drug Administration (FDA) authority ... on tobacco marketing and sales to kids. The U.S. ... House has approved similar legislation, and Congress is expected to ...

... , WASHINGTON, June 11 The following statement of CEO ... Prevention and Tobacco Control Act was released today by the ... taken a bold and courageous step to ensure a healthier ... Prevention and Tobacco Control Act. The legislation will allow ...

... Tobacco-Free Kids applauds U.S. Senators Olympia Snowe and Susan Collins ... U.S. Food and Drug Administration (FDA) authority to regulate tobacco ... and sales to kids. The U.S. Senate approved the ... similar legislation, and Congress is expected to quickly send a ...

... Scheduled for Friday, June 12, 2009 , , LANCASTER, ... ) today reported financial results for the third quarter ended May ... the thirteen weeks ended May 3, 2009 were approximately $41.8 million, ... ended May 4, 2008. , , Income from continuing operations ...

Senators Mikulski and Cardin Vote to Protect America's Kids From Tobacco Senators Murkowski and Begich Vote to Protect America's Kids from Tobacco Senators Lincoln and Pryor Vote to Protect America's Kids From Tobacco Statement by American Heart Association CEO Nancy Brown on Senate Passage of the Family Smoking Prevention and Tobacco Control Act June 11, 2009 Senators Snowe and Collins Vote to Protect America's Kids from Tobacco Herley Industries, Inc. Reports Third Quarter Earnings

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Porphyrins, Fecal Porphobilinogen (PBG) Deaminase, Erythrocyte Ponstel, Urine Polychlorinated Biphenyls, Blood